Shares of Syneos Health Inc (NASDAQ:SYNH) have been assigned an average recommendation of “Buy” from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $54.63.

A number of research firms have weighed in on SYNH. Wolfe Research initiated coverage on Syneos Health in a research note on Tuesday, April 2nd. They issued a “market perform” rating for the company. UBS Group downgraded Syneos Health from a “buy” rating to a “neutral” rating and set a $55.00 target price for the company. in a research note on Tuesday, March 19th. ValuEngine upgraded Syneos Health from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. William Blair reiterated an “outperform” rating on shares of Syneos Health in a research note on Tuesday, March 19th. Finally, Barclays reiterated a “hold” rating and set a $48.00 target price on shares of Syneos Health in a research note on Wednesday, April 17th.

SYNH stock traded down $0.53 during mid-day trading on Thursday, reaching $41.63. The company had a trading volume of 23,499 shares, compared to its average volume of 693,308. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 1.07. The company has a market cap of $4.37 billion, a price-to-earnings ratio of 15.84, a P/E/G ratio of 1.51 and a beta of 1.36. Syneos Health has a 52 week low of $36.26 and a 52 week high of $56.34.

Syneos Health (NASDAQ:SYNH) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.59 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.08. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Syneos Health had a return on equity of 9.55% and a net margin of 0.42%. The business’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $0.55 earnings per share. On average, equities research analysts anticipate that Syneos Health will post 2.67 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. NumerixS Investment Technologies Inc acquired a new stake in Syneos Health during the 4th quarter worth approximately $57,000. Boston Advisors LLC acquired a new position in Syneos Health in the 4th quarter valued at $2,121,000. Oregon Public Employees Retirement Fund raised its holdings in Syneos Health by 9.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 24,127 shares of the company’s stock valued at $949,000 after acquiring an additional 2,085 shares in the last quarter. BB&T Corp raised its holdings in Syneos Health by 14.2% in the 4th quarter. BB&T Corp now owns 7,538 shares of the company’s stock valued at $296,000 after acquiring an additional 936 shares in the last quarter. Finally, Sapience Investments LLC raised its holdings in Syneos Health by 4.7% in the 4th quarter. Sapience Investments LLC now owns 379,935 shares of the company’s stock valued at $14,950,000 after acquiring an additional 16,955 shares in the last quarter.

About Syneos Health

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Recommended Story: Why does the United States have a lingering trade deficit?

Analyst Recommendations for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.